- Report
- June 2024
- 118 Pages
Global
From €4165EUR$4,650USD£3,550GBP
- Report
- June 2025
- 178 Pages
Global
From €5240EUR$5,850USD£4,467GBP
- Report
- June 2025
- 138 Pages
Global
From €5240EUR$5,850USD£4,467GBP
- Report
- May 2025
- 185 Pages
Global
From €3426EUR$3,825USD£2,920GBP
€4031EUR$4,500USD£3,436GBP
- Drug Pipelines
- April 2025
- 204 Pages
Global
From €2687EUR$3,000USD£2,291GBP
- Report
- October 2024
- 200 Pages
Global
From €3359EUR$3,750USD£2,863GBP
- Report
- May 2025
- 183 Pages
Global
From €3175EUR$3,545USD£2,707GBP
€3528EUR$3,939USD£3,008GBP
- Report
- February 2025
- 190 Pages
Global
From €4298EUR$4,799USD£3,664GBP
- Report
- December 2024
- 325 Pages
Global
From €4298EUR$4,799USD£3,664GBP
- Report
- November 2024
- 1159 Pages
Global
€1821EUR$2,104USD£1,500GBP
- Report
- May 2025
- 483 Pages
Global
From €5282EUR$6,103USD£4,350GBP
- Report
- February 2025
- 434 Pages
Global
From €4434EUR$4,950USD£3,779GBP
- Report
- November 2024
- 498 Pages
Global
From €4434EUR$4,950USD£3,779GBP
- Report
- April 2025
- 469 Pages
Global
From €4434EUR$4,950USD£3,779GBP
- Report
- March 2025
Global
From €4389EUR$4,900USD£3,741GBP
- Report
- March 2025
- 184 Pages
Global
From €4165EUR$4,650USD£3,550GBP
- Report
- May 2025
- 188 Pages
Global
From €3175EUR$3,545USD£2,707GBP
€3528EUR$3,939USD£3,008GBP
- Report
- May 2025
- 188 Pages
Global
From €3175EUR$3,545USD£2,707GBP
€3528EUR$3,939USD£3,008GBP
- Report
- May 2025
- 190 Pages
Global
From €3175EUR$3,545USD£2,707GBP
€3528EUR$3,939USD£3,008GBP
- Report
- May 2025
- 197 Pages
Global
From €3175EUR$3,545USD£2,707GBP
€3528EUR$3,939USD£3,008GBP

RNA interference (RNAi) is a biotechnological process that uses small pieces of double-stranded RNA (dsRNA) to inhibit gene expression. It is a powerful tool for studying gene function and has been used to develop treatments for a variety of diseases. RNAi has been used to target and silence specific genes, allowing researchers to study the effects of gene silencing on cell function. It has also been used to develop treatments for cancer, viral infections, and other diseases.
RNAi technology has been used to develop a variety of therapeutics, including small interfering RNAs (siRNAs), microRNAs (miRNAs), and antisense oligonucleotides (ASOs). siRNAs are short pieces of dsRNA that can be used to target and silence specific genes. miRNAs are small pieces of single-stranded RNA that can regulate gene expression. ASOs are short pieces of DNA that can be used to target and silence specific genes.
The RNAi market is a rapidly growing segment of the biotechnology industry. Companies in the market include Alnylam Pharmaceuticals, Arrowhead Pharmaceuticals, BioNTech, Editas Medicine, and Moderna Therapeutics. These companies are developing a variety of RNAi-based therapeutics for a range of diseases. Show Less Read more